Vessey M P, Villard-Mackintosh L, McPherson K, Yeates D
Department of Community Medicine and General Practice, Radcliffe, Infirmary, Oxford.
BMJ. 1989 Dec 16;299(6714):1487-91. doi: 10.1136/bmj.299.6714.1487.
To see whether the use of oral contraceptives influences mortality.
Non-randomised cohort study of 17,032 women followed up on an annual basis for an average of nearly 16 years.
17 Family planning clinics in England and Scotland.
Women recruited during 1968-74. At the time of recruitment each woman was aged 25-39, married, a white British subject, willing to participate, and either a current user of oral contraceptives or a current user of a diaphragm or intrauterine device (without previous exposure to the pill).
Overall mortality and cause specific mortality.
238 Deaths occurred during the follow up period. The main analyses concerned women entering the study while using either oral contraceptives or a diaphragm or intrauterine device. The overall relative risk of death in the oral contraceptive users was 0.9 (95% confidence interval 0.7 to 1.2). Though the numbers of deaths were small in most individual disease categories, the trends observed were generally consistent with findings in other reports. Thus the relative risk of death in the oral contraceptive users was 4.9 (95% confidence interval 0.7 to 230) for cancer of the cervix, 3.3 (95% confidence interval 0.9 to 17.9) for ischaemic heart disease, and 0.4 (95% confidence interval 0.1 to 1.2) for ovarian cancer. There was a linear trend in the death rates from cervical cancer and ovarian cancer (in opposite directions) with total duration of oral contraceptive use. Death rates from breast cancer (relative risk 0.9; 95% confidence interval 0.5 to 1.4) and suicide and probable suicide (relative risk 1.1; 95% confidence interval 0.3 to 3.6) were much the same in the two contraceptive groups. In 1981 the relative risk of death in oral contraceptive users from circulatory diseases as a group was reported to be 4.2 (95% confidence interval 2.3 to 7.7) in the Royal College of General Practitioners oral contraception study. The corresponding relative risk in this study was only 1.5 (95% confidence interval 0.7 to 3.0).
These findings contain no significant evidence of any overall effect of oral contraceptive use on mortality. None the less, only small numbers of deaths occurred during the study period and a significant adverse (or beneficial) overall effect might emerge in the future. Interestingly, the mortality from circulatory disease associated with oral contraceptive use was substantially less than that found in the Royal College of General Practitioners study.
探讨口服避孕药的使用是否会影响死亡率。
对17032名女性进行非随机队列研究,每年随访一次,平均随访近16年。
英格兰和苏格兰的17家计划生育诊所。
1968年至1974年招募的女性。招募时,每位女性年龄在25至39岁之间,已婚,为英国白人,愿意参与研究,且当时正在使用口服避孕药或子宫托或宫内节育器(以前未接触过避孕药)。
总死亡率和特定病因死亡率。
随访期间有238人死亡。主要分析涉及在开始研究时使用口服避孕药或子宫托或宫内节育器的女性。口服避孕药使用者的总死亡相对风险为0.9(95%置信区间0.7至1.2)。尽管大多数个体疾病类别中的死亡人数较少,但观察到的趋势总体上与其他报告的结果一致。因此,口服避孕药使用者患宫颈癌的死亡相对风险为4.9(95%置信区间0.7至230),患缺血性心脏病的为3.3(95%置信区间0.9至17.9),患卵巢癌的为0.4(95%置信区间0.1至1.2)。宫颈癌和卵巢癌的死亡率(方向相反)与口服避孕药的总使用时长呈线性趋势。两组避孕药使用者的乳腺癌死亡率(相对风险0.9;95%置信区间0.5至1.4)以及自杀和疑似自杀死亡率(相对风险1.1;95%置信区间0.3至3.6)大致相同。1981年,皇家全科医师学院口服避孕药研究报告称,口服避孕药使用者患循环系统疾病的死亡相对风险为4.2(95%置信区间2.3至7.7)。本研究中的相应相对风险仅为1.5(95%置信区间0.7至3.0)。
这些研究结果没有显著证据表明口服避孕药的使用对死亡率有任何总体影响。尽管如此,研究期间死亡人数较少,未来可能会出现显著的不良(或有益)总体影响。有趣的是,与口服避孕药使用相关的循环系统疾病死亡率明显低于皇家全科医师学院研究中的发现。